Projected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic
In this study, the potential eligibility rate by AUC of the entire patient cohort (5.9%) was limited by the small proportion of patients who had CSF testing for AD biomarkers. So while disease-modification with Lecanemab is a welcome therapeutic advance, although only a small proportion of people currently attending specialist services will be eligible. Successful delivery of DMTs will require significant resource allocation and optimisation of referral pathways to facilitate early identification of potentially eligible patients.
Authors
- Helena Dolphin (ORCID: https://orcid.org/0000-0001-5540-7850)
- Antoinette O’Connor (ORCID: https://orcid.org/0000-0003-4467-128X)
- Seán O’Dowd (ORCID: https://orcid.org/0000-0002-5102-6230)
- Adam H. Dyer (ORCID: https://orcid.org/0000-0003-1356-510X)
- Aoife Fallon (ORCID: https://orcid.org/0000-0002-2912-7297)
- Seán Kennelly (ORCID: https://orcid.org/0000-0002-3721-0197)
- Eimear Connolly (ORCID: https://orcid.org/0000-0002-9896-8305)
Institutions
- Trinity College Dublin (IE)
- Tallaght University Hospital (IE)
Publication Details
- Journal
- International Journal of Geriatric Psychiatry
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/gps.6157
- Citations
- 6
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.31
Funders
- Canadian Institute for Theoretical Astrophysics
- Wellcome Trust
- Health Service Executive
- Irish Research eLibrary
- Meath Foundation